MOGAD – Medxy AI

Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4+ NMOSD: Unraveling the Impact of Disease Activity in MOGAD

By MedXY 10/28/2026

This review synthesizes evidence comparing brain atrophy patterns in MS, MOGAD, and AQP4+ NMOSD, highlighting MOGAD's atrophy association with inflammatory activity and lesion dynamics, emphasizing distinct pathogenic mechanisms and clinical trajectories.

Neurology news Pediatrics

Early Escalation of Acute Treatment Reduces Relapse Risk in Pediatric MOG Antibody-Associated Disease

By MedXY 08/25/2026

In pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), escalation of acute immunotherapy beyond steroids at first attack is linked to significantly fewer relapses within one year and mid-term follow-up, highlighting a critical therapeutic window to alter disease trajectory.

Allergy & Immunology Neurology news

Interleukin 6 Receptor Blockade: A Promising Strategy for Relapse Prevention in MOG Antibody-Associated Disease

By MedXY 07/16/2026

IL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.

Neurology news

Disability Dynamics Independent of Attacks in AQP4-IgG+ NMOSD and MOGAD: Insights from a Multicenter Cohort Study

By MedXY 07/03/2026

This study reveals that disability improvement and worsening independent of attacks, though rare, occur in AQP4-IgG+ NMOSD and MOGAD. Early attack prevention and younger age are key factors influencing disability trajectories.

Neurology news Public Health

French Registry Data Show Marked Declines in Relapse Activity and Faster Diagnosis in AQP4+NMOSD and MOGAD From 2010 to 2024

By MedXY 05/26/2026

A nationwide French cohort found earlier diagnosis, falling relapse rates, and major treatment shifts in AQP4+NMOSD and MOGAD, with rituximab linked to lower disability risk in AQP4+NMOSD and overall milder disability trajectories in MOGAD.

Neurology news

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

By MedXY 05/13/2026

In adults with MOGAD, stopping maintenance therapy was associated with a low 1-year relapse risk, especially after longer treatment and a longer relapse-free interval. The findings support individualized decisions and close follow-up after discontinuation.

Neurology news Ophthalmology

Why the New MS Diagnostic Criteria Require Caution: High Frequency of MOGAD and NMOSD in Optic Neuritis Patients

By MedXY 03/30/2026

A retrospective study reveals that 24% of patients meeting the latest MS criteria following optic neuritis actually have MOGAD or NMOSD, emphasizing the need for antibody testing to prevent misdiagnosis.

Neurology news Ophthalmology

Navigating the Diagnostic Overlap: Why 24 Percent of Patients Meeting Minimal MS Criteria for Optic Neuritis Require Antibody Testing

By MedXY 03/18/2026

A multicenter study reveals that nearly one-quarter of patients meeting the newest multiple sclerosis criteria for optic neuritis actually have MOGAD or NMOSD, emphasizing the critical role of antibody screening and detailed orbital MRI in clinical practice.